Taken together, our present work defines the optimal application scheme and dose of antigen and adjuvants for the non-invasive vaccination platform DIVA leading to tumor protective CD8 and CD4 T-cell responses in a rodent model. This evidence concerns the gene CD8A and neoplasm.